Search results for " neck"

showing 10 items of 489 documents

DRH1 - a novel blood-based HPV tumour marker.

2020

Abstract Background To date, no studies have successfully shown that a highly specific, blood-based tumour marker to detect clinically relevant HPV-induced disease could be used for screening, monitoring therapy response or early detection of recurrence. This study aims to assess the clinical performance of a newly developed HPV16-L1 DRH1 epitope-specific serological assay. Methods In a multi-centre study sera of 1486 patients (301 Head and Neck Squamous Cell Carcinoma (HNSCC) patients, 12 HIV+ anal cancer patients, 80 HIV-positive patients, 29 Gardasil-9-vaccinees, 1064 healthy controls) were tested for human HPV16-L1 DRH1 antibodies. Analytical specificity was determined using WHO referen…

0301 basic medicineMaleResearch paperlcsh:MedicineHIV InfectionsDiseaseGastroenterologyHNSCC0302 clinical medicineNeoplasmsTumour markerMedicineProspective StudiesAged 80 and overlcsh:R5-920Human papillomavirus 16medicine.diagnostic_testbiologyGeneral MedicineMiddle AgedAnus NeoplasmsVaccinationHead and Neck Neoplasms030220 oncology & carcinogenesisArea Under CurveCarcinoma Squamous CellScreeningBiomarker (medicine)FemaleAntibodylcsh:Medicine (General)Blood testAdultHPV16medicine.medical_specialtyEarly detectionSensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologyAntibodies03 medical and health sciencesInternal medicineBiomarkers TumorBlood testAnal cancerHumansPapillomavirus VaccinesAgedbusiness.industrylcsh:RPapillomavirus InfectionsOncogene Proteins Viralmedicine.diseaseHead and neck squamous-cell carcinoma030104 developmental biologyCross-Sectional StudiesCase-Control Studiesbiology.proteinCapsid ProteinsbusinessCarrier ProteinsEBioMedicine
researchProduct

Effects of exercise frequency and training volume on bone changes following a multi-component exercise intervention in middle aged and older men: Sec…

2021

Progressive resistance training (PRT) combined with weight-bearing impact exercise are recommended to optimize bone health, but the optimal frequency and dose of training remains uncertain. This study, which is a secondary analysis of an 18-month intervention in men aged 50–79 years, examined the association between exercise frequency and the volume of training with changes in DXA and QCT-derived femoral neck (FN) and lumbar spine (LS) bone outcomes, respectively. Men were allocated to either thrice-weekly PRT plus impact exercise training (n = 87) or a non-exercising (n = 85) group. Average weekly exercise frequency (ExFreq) and training volume per session [PRT volume (weight lifted, kg), …

0301 basic medicineMalemedicine.medical_specialtyHistologyweight-bearing exercisePhysiologyEndocrinology Diabetes and Metabolismluuntiheys030209 endocrinology & metabolismlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawBone DensitySecondary analysisMedicineHumansolder menExerciseFemoral neckAgeddose-responsekehonpainoharjoitteluLumbar VertebraeExercise interventionbusiness.industryFemur NeckResistance trainingResistance TrainingMiddle Agedkeski-ikäiset030104 developmental biologymedicine.anatomical_structurePhysical therapyLumbar spinemiehetvoimaharjoitteluresistance trainingbusinessbone mineral densityExercise frequencyikääntyneetVolume (compression)Bone
researchProduct

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and…

2019

Abstract Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN. Methods A total of 180 patients with R/M SCCHN (1:1) were assigned to receive either cisplatin (40 mg/m2), docetaxel (40 mg/m2) and 5-FU (2000 mg/m2) at days 1 and 8 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (DPFC) or standard cisplatin (100 mg/m2) at day 1, 5-FU (1000 mg/m2) at days 1–4 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (PFC). Chemotherapy was…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinCetuximabDocetaxelDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAgedCisplatinChemotherapyCetuximabbusiness.industrySquamous Cell Carcinoma of Head and NeckHead and neck cancerHazard ratioMiddle AgedInterim analysismedicine.disease030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisFemaleFluorouracilCisplatinbusinessmedicine.drug
researchProduct

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

2018

Current treatment options for advanced and recurrent head and neck squamous cell carcinoma (HNSCC) enclose radiation and chemo-radiation approaches with or without surgery. While platinum-based chemotherapy regimens currently represent the gold standard in terms of efficacy and are given in the vast majority of cases, new chemotherapy regimens, namely immunotherapy are emerging. However, the response rates and therapy resistance mechanisms for either chemo regimen are hard to predict and remain insufficiently understood. Broad variations of chemo and radiation resistance mechanisms are known to date. This study describes the development of a standardized, high-throughput in vitro assay to a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGeneral Chemical Engineeringmedicine.medical_treatmentCell Culture TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences3D cell culture0302 clinical medicineInternal medicinemedicineCarcinomaHumansPrecision MedicineChemotherapyGeneral Immunology and MicrobiologySquamous Cell Carcinoma of Head and Neckbusiness.industryGeneral NeuroscienceHead and neck cancerImmunotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good healthRegimen030104 developmental biologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellPersonalized medicinebusinessJournal of Visualized Experiments
researchProduct

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

2018

Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiv…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisDerived neutrophil-to-lymphocyte ratio; Head and neck squamous cell carcinoma; Inflammation-based prognostic scores; Neutrophil-to-lymphocyte ratio; Overall survival; Prognostic factors; Prognostic nutritional indexoverall survivalhead and neck squamous cell carcinomaderived neutrophil-to-lymphocyte ratio03 medical and health sciences0302 clinical medicineneutrophil-to-lymphocyte ratioInternal medicinemedicine1506Stage (cooking)Neutrophil to lymphocyte ratioOriginal ResearchUnivariate analysisbusiness.industryHead and neck cancerInduction chemotherapyprognostic factorsprognostic nutritional indexmedicine.diseaseHead and neck squamous-cell carcinomaClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisinflammation-based prognostic scoresbusinessESMO open
researchProduct

Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer.

2017

Background/Aim: Chemo-radiation currently serves as first-line therapy of advanced and recurrent head and neck cancer, while new chemotherapy regimens are emerging. However, response rates to any treatment are difficult to predict and underlie broad variation. This study shows the development of a standardized, high-throughput in vitro assay to assess patients' individual response to therapy regimens as a future tool for personalized tumor therapy. Materials and Methods: Viability and proliferation analyses after chemo +/- radiation treatment of single spheroids (low adhesion plates/Hanging Drop (HD)) were generated from head and neck squamous cell carcinoma (HNSCC) cell lines and primary h…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyNecrosismedicine.medical_treatmentCell Culture TechniquesAntineoplastic Agents03 medical and health sciences3D cell culture0302 clinical medicineInternal medicineCell Line TumorSpheroids CellularDrug DiscoverymedicineTumor Cells CulturedHumansPrecision MedicineChemotherapybusiness.industryHead and neck cancerSpheroidGeneral MedicineChemoradiotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good health030104 developmental biologyOncologyCell cultureHead and Neck Neoplasms030220 oncology & carcinogenesisPersonalized medicinemedicine.symptomDrug Screening Assays AntitumorbusinessAnticancer research
researchProduct

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

2020

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p &lt

0301 basic medicineOncologyMale<i>MET</i> copy numbermedicine.medical_treatmentproteínas protooncogénicas c-metdosificación génicahumanosresistencia a medicamentosDrug ResistanceGene Dosagecirculating free DNA (cfDNA)<i>MET</i> amplificationTargeted therapyTargeted therapy0302 clinical medicineCirculating tumor cellestudios prospectivosNeoplasmsantineoplásicosProspective Studieslcsh:QH301-705.5Circulating tumor cells (CTCs)neoplasiasGeneral MedicineProto-Oncogene Proteins c-mettargeted therapyNeoplastic Cells CirculatingErbB ReceptorsCell-free fetal DNA030220 oncology & carcinogenesisinhibidores de proteína cinasasBiomarker (medicine)FemaleMET protein expressionCell-Free Nucleic AcidsMET amplificationmedicine.medical_specialtycirculating tumor cells (CTCs)estudios de casos y controlesMet amplificationCirculating free DNA (cfDNA)Antineoplastic AgentsArticle03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansLiquid biopsyProtein Kinase InhibitorsRetrospective Studiesbusiness.industryHead and neck cancerestudios retrospectivosLiquid BiopsyCancermedicine.disease030104 developmental biologylcsh:Biology (General)Drug Resistance NeoplasmCase-Control StudiesMET copy numberbusinessCells
researchProduct

Ectopic myoglobin expression is associated with a favourable outcome in head and neck squamous cell carcinoma patients

2016

BACKGROUND/AIM: Ectopic myoglobin (MB) expression, mediated by alternative and hypoxia-inducible transcription, has recently been demonstrated in several epithelial tumours. This study aimed to examine the expression of MB in hormone-independent head and neck squamous cell carcinomas (HNSCCs). PATIENTS AND METHODS: Using imunohistochemistry, ectopic MB expression was analyzed on tissue microarrays (TMAs) of 524 patients with localized and locally advanced primary and recurrent HNSCC who had undergone surgical treatment with curative intent. Associations of MB expression with survival and clinicopathological parameters were analyzed. RESULTS: MB expression was found in 45.8% of HNSCC patient…

0301 basic medicineOncologyMaleCancer ResearchPathologyCellMedizinchemistry.chemical_compound0302 clinical medicineMedicine1306 Cancer ResearchHead and neckSurgical treatmentChildTissue microarrayMyoglobinHazard ratioGeneral MedicineMiddle Aged10081 Institute of Veterinary Physiologymedicine.anatomical_structureTreatment OutcomeOncologyMyoglobinHead and Neck Neoplasms030220 oncology & carcinogenesisChild PreschoolCarcinoma Squamous CellFemale2730 OncologyAdultmedicine.medical_specialtyHPVAdolescenthead and neck squamous cell carcinoma03 medical and health sciencesYoung AdultInternal medicineHumansbusiness.industryInfant NewbornInfantmedicine.diseaseHead and neck squamous-cell carcinomaConfidence interval030104 developmental biologychemistry570 Life sciences; biologyprognosisbusiness
researchProduct

Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results from an EORTC led survey

2018

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryLocally advancedHematologymedicine.diseaseHead and neck squamous-cell carcinoma03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinebusiness
researchProduct

Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma

2017

Background Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells can be used to predict the malignant transformation of potentially malignant disorders and the metastatic tendency of primary head and neck squamous cell carcinoma. The aim of our study was to compare the expression of podoplanin in oral leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma with that in normal buccal mucosa by immunohistochemical methods. Material and methods Immunohistochemical expression of podoplanin was analyzed in 20 cases each of or…

0301 basic medicinePathologymedicine.medical_specialtymedicine.drug_classgovernment.form_of_governmentMonoclonal antibodyMalignant transformation03 medical and health sciences0302 clinical medicineDownregulation and upregulationmedicineGeneral DentistryOral Medicine and Pathologybusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Head and neck squamous-cell carcinomaLymphatic Endotheliumstomatognathic diseases030104 developmental biologyOral submucous fibrosisPodoplanin030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASgovernmentImmunohistochemistrybusiness
researchProduct